ContraFect Corporation

NASDAQ: CFRXHealthcare / Biotechnology / USA
0.4700+0.0100+2.17%Vol 218 8281Y Perf -76.75%
Jun 14th, 2019 16:00
BID0.4600 ASK0.4600
Open0.4500 Previous Close0.4700
Pre-Market- After-Trading-
 - -%  - -%
Target Price
2.63 
Analyst Rating
Strong Buy 1.00
Potencial %
459.57 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)37 
Earnings Rating
Strong Buy
Price Range Ratio 52wk %
4.65 
Earnings Date
8th Aug 2019

Today's Price Range

0.45000.4800

52wk Range

0.35002.93

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Sell
Performance
1 Month
-6.00%
3 Months
27.03%
6 Months
-77.40%
1 Year
-76.75%
3 Years
-84.12%
5 Years
-

Name / TickerPriceChg.Chg.%
CFRX0.47000.01002.17
AAPL192.74-1.4100-0.73
GOOG1 085.35-3.4200-0.31
MSFT132.450.13000.10
XOM74.35-0.3300-0.44
WFC45.590.30000.66
JNJ140.09-0.6200-0.44
FB181.333.86002.18
GE10.23-0.0800-0.78
JPM109.820.28000.26
Earnings HistoryEstimateReportedSurprise %
Q01 2019-0.100.15250.00
Q04 2018-0.10-0.0820.00
Q03 2018-0.10-0.100.00
Q02 2018-0.10-0.100.00
Q01 2018-0.09-0.090.00
Q04 2017-0.10-0.12-20.00
Q03 2017-0.110.04136.36
Q02 2017-0.16-0.156.25
Earnings Per EndEstimateRevision %Trend
6/2019 QR-0.0910.00Positive
9/2019 QR-0.0820.00Positive
12/2019 FY-0.1462.16Positive
12/2020 FY-0.387.32Positive
Next Report Date8th Aug 2019
Estimated EPS Next Report-0.09
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume218 828
Shares Outstanding (in ths.)79 410
Trades Count297
Dollar Volume98 101
Avg. Volume1 207 089
Avg. Weekly Volume850 698
Avg. Monthly Volume1 251 660
Avg. Quarterly Volume1 370 383
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

ContraFect Corporation

ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases.

CEO: Roger J. Pomerantz

Teplephone: +1 914 207-2300

Address: 28 Wells Avenue, Yonkers 10701, NY, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

57%43%

News